NCT01748825View on ClinicalTrials.gov

AZD1775 for Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 19, 2012

Primary Completion Date

May 19, 2020

Study Completion Date

May 19, 2020

Conditions
Solid Tumors
Interventions
DRUG

MK-1775 (AZD1775)

MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01748825 - AZD1775 for Advanced Solid Tumors | Biotech Hunter | Biotech Hunter